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Abstract Modern transplantation of cells, tissues
and organs has been practiced within the last century
achieving both life saving and enhancing results.
Associated risks have been recognized including
infectious disease transmission, malignancy, immune
mediated disease and graft failure. This has resulted
in establishment of government regulation, profes-
sional standard setting and establishment of vigilance
and surveillance systems for early detection and
prevention and to improve patient safety. The
increased transportation of grafts across national
boundaries has made traceability difﬁcult and some-
times impossible. Experience during the ﬁrst Gulf
War with miss-identiﬁcation of blood units coming
from multiple countries without standardized coding
and labeling has led international organizations to
develop standardized nomenclature and coding for
blood. Following this example, cell therapy and tissue
transplant practitioners have also moved to standard-
ization of coding systems. Establishment of an
international coding system has progressed rapidly
and implementation for blood has demonstrated
multiple advantages. WHO has held two global
consultations on human cells and tissues for trans-
plantation, which recognized the global circulation of
cells and tissues and growing commercialization and
the need for means of coding to identify tissues and
cells used in transplantation, are essential for full
traceability. There is currently a wide diversity in the
identiﬁcation and coding of tissue and cell products.
For tissues, with a few exceptions, product terminol-
ogy has not been standardized even at the national
level. Progress has been made in blood and cell
therapies with a slow and steady trend towards
implementation of the international code ISBT 128.
Across all ﬁelds, there are now 3,700 licensed
facilities in 66 countries. Efforts are necessary to
encourage the introduction of a standardized interna-
tional coding system for donation identiﬁcation
numbers, such as ISBT 128, for all donated biologic
products.
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Development of cell, tissue and organ
transplantation
The history of skin grafts has its beginnings in
ancient India, where Sanskrit texts document skin
transplants performed by Hindus in 3000–2500 BC
(Herman 2002). The concept of transplantation of
body parts from one individual to another can be
found in paintings from the Middle Ages depicting
the transplanting of a leg from an African donor to an
Italian noble. Even grafting of animal bone to a
human was described as early as 1668. The ﬁrst
clinical autograft was performed in Germany in 1820
and the ﬁrst human bone allograft in 1880 in Scotland
(DeBoer 1986). Eduard Zirm performed the ﬁrst
corneal transplant in Vienna, Austria in 1905, initi-
ating this practice in ophthalmology (Moffat et al.
2005). Alexis Carrel is credited with the earliest
studies on the storage of tissues and was prophetic in
his predictions of the use of cadavers for organ and
tissue donation. He was the ﬁrst to transplant vascular
tissues (Carel 1912) and was the recipient of a Nobel
Prize.
The use of banked tissues in surgical procedures is
credited to Albee who used both autologous and
allogeneic-banked bone as early as 1910 (Albee
1912). The ﬁrst eye bank opened in New York in
1944, marking the ﬁrst organized attempt at banking
donor tissue, facilitating the transfer of eye tissue
from donor to recipient. It wasn’t until the 1940s that
bone banking became common practice, primarily
with autologous grafts (Wilson 1947; Bush and
Garber 1948). Established in 1961 by the American
Academy of Ophthalmology’s Committee on Eye
Banks, the Eye Bank Association of America is the
oldest national transplantation association, leading
the transplant ﬁeld with the establishment of medical
standards for the procurement and distribution of
eyes, comprehensive education programs for techni-
cians, and accreditation of eye banks. Modern day
tissue banking was initiated in the US Navy in 1949
and many of today’s standards are due to their
experience over several decades along with the
establishment of the American Association of Tissue
Banks (AATB) in 1976 (Strong 2000). By the early
1950s, tissue banks were also established in Europe.
By 1971, the recognition that ionizing radiation was
being used to sterilize tissue (non-ocular) engaged the
International Atomic Energy Agency (IAEA), which
sponsored an expert meeting in Hungary (Phillips and
Strong 1997). Over the ensuing years, assistance was
provided to developing countries in both Asia and
South America and workshops, training programmes
and educational materials were provided. Support for
Tissue Banks was provided for: Argentina, Bangla-
desh, Brazil, Chile, China, Cuba, India, Indonesia,
Republic of Korea, Malaysia, Pakistan, Philippines,
Singapore, Sri Lanka, Thailand and Vietnam. In
addition training scholarships were provided for
individuals from these countries as well as partici-
pants from countries such as Algeria, Turkey, Hun-
gary, Costa Rica, Peru, Mexico and Zambia to train in
established tissue banks in Europe and the United
States. As an example of the success of these
programmes, the Sri Lanka Eye Donation Society
had distributed over 33,000 corneas by the mid
1980s.
The early clinical success with bone and corneal
transplants was due to the non-vascularized nature of
such grafts. The use of organs was impeded until the
recognition of the histocompatibility system, ﬁrst
described in 1951 (Billingham and Medawar 1951),
which led to a Nobel Prize. Their work also led to the
discovery of glycerol as a cryopreservative for skin
thus opening the possibilities for skin banking for the
treatment of burns. Dr Joseph Murray performed the
ﬁrst successful kidney transplant, between identical
twins, in 1954, which also led to a Nobel Prize and
the advent of solid organ transplantation (Guild et al.
1955). Dr Murray shared the Prize with Dr E. Donnell
Thomas who was instrumental in advancing the ﬁeld
of bone marrow transplantation (Thomas et al. 1957).
Both the solid organ and stem cell transplantation
ﬁelds have been able to progress due to advances in
immunosuppressive drugs and histocompatibilty
matching. Establishment of organ sharing networks
in developed countries such as the United Network
for Organ Sharing in the U.S. and Eurotransplant for
some countries in Europe, along with registries for
unrelated stem cell transplants such as the Anthony
Nolan Trust in the United Kingdom, OneMatch in
Canada and the National Marrow Donor Program in
the U.S. have expanded the scope and ability to share
these valuable resources worldwide.
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123Advances in healthcare technologies have led to
an increasing number and wider array of tissues of
human origin being collected to sustain and improve
the quality of life. Solid organs, corneas and eye
tissues, including sclera, bone, skin, and stem cells,
are all examples of human tissues derived from
living or deceased donors, otherwise known as
allografts. In the United States in 2007, 28,000
organs, 50,000 corneas, 18,000 stem cell grafts and
over two million tissue allografts were distributed.
Despite the increase in numbers over time, demand
often exceeds supply, particularly for solid organs.
In the U.S., over 100,000 patients are on waiting
lists for organ transplants. Efforts to increase the
availability of these vital products generate chal-
lenges to monitor and ensure appropriate access and
safety both in the domestic and global arenas since
these products often cross national boundaries.
Moreover, the lucrative nature of the selling of so-
called ‘‘body parts’’ has generated unethical behav-
ior. Recent scandals such as the trafﬁcking of solid
organs sold from Israel to New York (Feyerick
2009) and the alleged theft of tissues from Ukraine
(Keller and Grill 2009) have generated much
interest in the press and exemplify the global nature
of the problem (Chaney 2006). In addition to
importation of organs and tissues, patients are
traveling abroad to receive organ transplants and
thus the risk of importing new diseases in immu-
nosuppressed recipients is ampliﬁed.
Noting the global increase in allogeneic transplan-
tation of cells, tissues and organs, the World Health
Organization (WHO) urged member states:
To implement effective national oversight of pro-
curement, processing and transplantation of human
cells, tissues and organs, including ensuring account-
ability for human material for transplantation and
traceability.
To cooperate in the formulation of recommenda-
tions and guidelines to harmonize global practices in
the procurement, processing and transplantation of
human cells, tissues and organs, including develop-
ment of minimum criteria for suitability of donors of
tissues and cells.
Toconsidersettingupethicscommissionstoensure
the ethics of cell, tissue and organ transplantation.
To extend the use of living kidney donations when
possible, in addition to donations from deceased
donors.
To take measures to protect the poorest and
vulnerable groups from ‘‘transplant tourism’’ and
the sale of tissues and organs, including attention to
the wider problem of international trafﬁcking in
human tissues and organs (WHO 2006).
Risks associated with cells, tissues and organs
The transmission of infections or malignancies to
recipientsofsolidorgans,tissues,andeyegraftsiswell
documented (Fishman 2007; Eastlund and Strong
2004; Trotter 2008; Tugwell et al. 2005; Gandhi and
Strong 2007). Infectious pathogens can include
viruses, bacteria, parasites and prions. The risks of
ampliﬁcation of transmission increase when there are
multiple recipients from a common donor since as
many as 100 tissues and organs can be recovered from
a single donor. Due to the organ shortage in particular,
donors with known high-risk behavior are sometimes
accepted for organ transplantation which can result in
multiple infectious risks (Ahn and Cohen 2008). Other
adverse events can occur including malignancies,
reactions to toxins, unexpected malfunction, adverse
immunological responses and immune mediated dis-
ease transmissions and administrative errors.
In addition, the organ, tissue and eye banking
communities function independently and communi-
cation between them is inconsistent and often lack-
ing. This lack of a formal communication can result
in an inability to track organs and tissues from a
common donor. For example, a report in 2005
described a number of hepatitis C virus (HCV)
transmissions to several organ and tissue recipients
from a single donor. This case generated much
publicity because there were 91 grafts produced from
the donor (7 organs, 2 corneas and 82 other tissues),
44 transplants and 40 recipients in 16 states and 2
other countries over a period of 22 months. Three
organ recipients were infected and 32 of the tissue
recipients could be identiﬁed and tested of which 5
were HCV positive and infected. To date, no
recipient of the transplanted eye tissue has serocon-
verted (thus, the recipients remain HCV negative).
One tissue recipient could not be identiﬁed. All of the
tissue recipient infections would have been prevented
if recognition of infection in the organ recipients had
resulted in notiﬁcation of the tissue bank before tissue
was processed or released. More than 6 months
elapsed between recognition of the organ recipient
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processed (Tugwell et al. 2005). Events of this nature
can only be avoided by the introduction of a
comprehensive and uniﬁed traceability system cov-
ering all biologics derived from a single donor.
The recall of allograft tissues in the U.S. under-
scores the problem related to allograft safety. The
FDA, between 1994 and June 2007, recalled 61,607
tissue allografts. The vast majority of these (59,476 or
96.5%) were musculoskeletal allografts (Mroz et al.
2008).
Biologic-based products or technologies are
always likely to carry an inherent risk. While solid
organs and some tissues such as the cornea cannot be
altered to reduce infectivity, some tissue types can be
processed with chemicals or radiation For instance,
blood can be modiﬁed through leukocyte ﬁltration or
irradiation. However, no process can eliminate the
risk of transmission. The role of patient safety efforts
is to drive that risk to the lowest level reasonably
achievable without unduly decreasing the availability
of these life saving resources, so that the overall
beneﬁt outweighs risk. Risk must also be assessed
using vigilance and surveillance programmes which
to date have not been universally developed for
tissues and cells and are insufﬁciently developed for
organs through regional organ sharing programmes
such as UNOS in the U.S. The U.S. does require
mandatory reporting of infectious adverse reactions
to the FDA by regulated establishments, and eye
banks accredited by the EBAA comply with require-
ments to electronically report adverse reaction,
including those due to biologic dysfunction. The
successes of this reporting is made possible since eye
banks typically distribute ocular tissue directly to the
surgeon and identify the recipient prior to transplan-
tation. A critical component of a biovigilance system
is constructive feedback to ongoing analysis efforts.
The World Health Organization (WHO) guideline on
adverse event reporting emphasizes that the effec-
tiveness of surveillance systems should be measured
not only by transplant outcome data reporting and
analysis but also by the use of such systems to
improve patient safety through active response to
data that are generated (WHO 2005).
Vigilance and surveillance of tissues and cells
used in transplantation is a recent development all
over the world. Biovigilance was established in
France by a decree in 2003. The European Union
Standards and Training for the Inspection of Tissue
Establishments (EUSTITE) co-funded by the Euro-
pean Commission, is assisting member states by
providing guidance documents and training in the
areas of inspection and adverse event and reaction
reporting. The project has developed vigilance and
surveillance tools consistent with and complementary
to those existing, such as hemovigilance systems, and
under development globally. The Department of
Essential Health Technologies at the WHO has led
these efforts. A survey of member states conducted
early in the project indicated that most countries did
not have a system of vigilance in place for tissues and
cells. In line with the requirements of the European
Tissue and Cell Directives, almost all member states
have now set up such systems. The EUSTITE
vigilance tools have been piloted in 20 Member
States during 2008/2009 and over 300 adverse events
and reactions have been reported and assessed using
the tools. These tools are able to objectively evaluate
severity and imputability as well as impact assess-
ment of adverse reactions and events. The key
elements of the tools have been incorporated into
guidance produced by the European Commission to
member states for the compilation of their annual
vigilance reports.
Challenges for traceability of cells, tissues
and organs
During 2005, a report from the state of New York in
the U.S. identiﬁed a serious problem with tissue
recovery being done outside of all standards and
regulations. It was discovered that a non-AATB
accredited organization was recovering donors from
funeral homes without the permission of families,
without adequate medical screening, and were, in
many cases, falsifying records. Tissue was sold to a
number of tissue processing centres and distributed.
Over 1,000 donors were recovered during a three-
year period of time. Nearly 50,000 tissues were
produced of which 15,000 could be recalled prior to
transplantation. Over 25,000 tissues were distributed
to unsuspecting patients without appropriate testing
or medical review (Warren 2006). Because records
from these donors had been forged, over 2,000 of
these tissues were untraceable including 800 that had
been distributed outside of the United States. The real
concern however, is that even apart from these
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tracking many tissues, with the exception of corneal
tissue, or to detect adverse events from their use. In
fact, most of the reported infectious transmissions
from tissue transplants have included the inability to
identify common recipients of tissues from the same
donor (applicable to tissues, not eyes).
Voluntary standard setting organizations, such as
the AATB and the European Association of Tissue
Banks (EATB) in Europe, have published standards
which require facilities that store and issue tissue,
including tissue distribution intermediaries, to main-
tain an adverse reaction ﬁle, develop recall proce-
dures and report adverse events and reactions to
Tissue Banks. Tissue Banks are required to maintain
adverse event policies and procedures including
reports that must be reviewed by the Medical
Director. Tissue Banks also include transplant
records/implant cards with each allograft that is
distributed. These records contain graft information.
Hospitals are requested to return these records
following transplants, although this is not required
of healthcare facilities, unless accredited by the Joint
Commission (TJC). Unfortunately, unless accredited
by the TJC, compliance with returns cannot be
enforced, which can hinder investigations and trace-
ability. AATB also perform periodic surveys of its
members to determine statistics concerning donation
and distribution. These surveys have demonstrated
that compliance with the return of transplant records
ranges from 10 to 95% thus further emphasizing the
difﬁculties with traceability.
In 1991, the Medical Advisory Board of the The
Eye Bank Association of America (EBAA) instituted
a requirement for its member eye banks to seek three
to twelve month follow-up reporting of all cornea
recipient outcomes. Their Adverse Reaction Registry
System (OARRS) was redesigned in 2005 for online
submissions of adverse reactions deemed ‘‘reason-
ably likely due to donor tissue.’’ Through its Medical
Advisory Board, OARRS submissions are reviewed
and reported to EBAA members on a biannual basis.
Eye banks employ a number of methods to seek the
follow-up outcomes, including regular mailings to
transplant surgeons, as well as providing institutions
with adverse reaction reporting forms. Information
submitted through OARRS includes a description of
the adverse reaction, date of surgery, microbiology
results, tissue mate status, data about the donor.
EBAA requires its members to seek recipient infor-
mation and outcomes as part of its accreditation
process. With a limited number of non-stocked ocular
tissues being distributed per donor, compliance is
easier to attain for eye banks.
In response to increased recognition of fatal events
due to diseases transmitted through organ transplan-
tation, there are relatively new policies in place to
require reporting of suspected disease transmission,
that are in the process of implementation. In the US
these efforts include the creation of a UNOS Disease
Transmission Advisory Committee (DTAC) to facil-
itate and monitor reports of organ donor-derived
practices for organ donors. These reports are required
under new UNOS policy. A total of 97 reports of
possible solid organ transplantation transmission
were reported to federal authorities in 2007 alone,
affecting a signiﬁcant percentage of the recipients of
over 28,000 organ transplantations annually.
Recently an estimate of the scope of disease trans-
mission has been roughly placed as involving
approximately 1% of recipients (Ison et al. 2009).
The Center for International Blood and Marrow
Transplant Research (CIBMTR) manages data on
hematopoietic cellular therapies (HCT) through an
afﬁliation with the International Bone Marrow Trans-
plant Registry (IBMTR) of the Medical College of
Wisconsin and the research arm of the National
Marrow Donor Program (NMDP). IBMTR is a
voluntary organization involving more than 400
transplant centers in 50 countries that have collabo-
rated to share patient data and conduct scientiﬁc
studies since 1972. They collect data from all U.S.
stem cell transplants and from about 25% of the rest
of the world. The NMDP was formally established in
1987 to provide unrelated donors for patients in need
of HCT. Their network includes 164 transplant
centers, 80 donor centers, 101 collection centers, 89
apheresis centers and 17 cord blood banks (CIBMTR
Progress Report 2008). Data are collected annually
on transplant recipients including follow-up informa-
tion on previously reported patients and adverse
reactions. Adverse events and reactions are also
monitored at the local center level using a variety of
center/hospital speciﬁc deﬁnitions.
In 2005 the Joint Commission (TJC) in the U.S.
published standards relating to tissue storage and
issuance. TJC accredits and certiﬁes more than
15,000 health care organizations and programs in
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with the lack of traceability was the recognition that
tissue is often dispersed among a variety of surgical
services with no central management, unlike trace-
able blood and pharmaceuticals which are distributed
within the hospital via licensed/accredited laborato-
ries and pharmacies, and organs where the recipient is
identiﬁed and recorded prior to the donation event,
tissue are distributed and stored within surgical
environments and can be mistaken and utilized as
mere ‘consumables’. Therefore the new standards
require the assignment of responsibility for handling
tissue within a hospital to a single coordinating entity.
The oversight responsibility includes: supplier certi-
ﬁcation, incoming inspection and logging in of tissue,
traceability and record keeping, storage temperature
monitoring, investigation of adverse outcomes,
reporting tissue-related infections to the tissue sup-
plier, sequestering tissue reported by the supplier as
contaminated, the notiﬁcation of surgeons and recip-
ients if tissue donors are subsequently found to harbor
infection, and compliance with federal and state
regulations if supplying tissues to any other facility.
Although compliance with TJC standards is volun-
tary, most hospitals in the U.S. comply with TJC
requirements in order to qualify for Medicare
reimbursement, and the College of American
Pathologists (CAP), the accrediting body of most
hospital laboratories, has adopted similar require-
ments. In many cases, hospitals have turned to their
blood bank where many of these capabilities are
already in existence.
Professional Associations also responded to the
problems of traceability by strengthening their stan-
dards and working to harmonize their standards with
that of the TJC. The AABB (formerly the American
Association of Blood Banks, both modiﬁed their
standards as well as published a series of handbooks
to assist hospital transfusion services to manage
tissue (Eisenbrey and Eastlund 2008).
The increased recognition of issues related to
traceability has also resulted in various governmental
actions in addition to existing regulations. In June
2005, the U. S. Centers for Disease Control and
Prevention (CDC), Food and Drug Administration
(FDA), and Health Resources and Services Admin-
istration (HRSA) convened a workshop entitled
‘‘Preventing Organ and Tissue Allograft-Transmitted
Infection: Priorities for Public Health Intervention.’’
Attendees included members from blood, organ and
tissue communities along with government represen-
tatives. This workshop identiﬁed gaps in organ and
tissue safety in the United States (Fishman et al.
2009). Four areas for possible intervention were
identiﬁed:
1. Communication among organ procurement orga-
nizations (OPOs), tissue banks, clinicians and
public health agencies related to donors, samples
and test results;
2. Tissue bank systems for tracking and notiﬁcation
of testing;
3. Hospital systems for tracking organs and tissues;
4. Recipient adverse event recognition. The work-
shop concluded that the most critical need was
for development of a communication network for
the tracking and reporting of disease transmis-
sions for tissues and organs. Such a network
would require a unique donor identiﬁer linking
organs and tissues, a tracking mechanism for all
allografts, and processes for reporting of adverse
events for the notiﬁcation of clinicians, patients,
and public health authorities.
As a result of the 2005 workshop, CDC published
a Request for Proposal for the development of a
‘‘Sentinel Network for Detecting Emerging Infections
Among Allograft Recipients’’ (Federal Register
2005). The United Network for Organ Sharing
(UNOS) on behalf of an alliance including: The
Association of Organ Procurement Organizations
(AOPO); the AATB; the Eye Bank Association of
America (EBAA); the American Society of Trans-
plantation (AST); and the American Society of
Transplant Surgeons (ASTS) submitted a proposal
and entered into a cooperative agreement with CDC
in 2006 to develop what was called the Transplan-
tation Transmission Sentinel Network (TTSN). The
purpose of the network was to provide a system for
detecting emerging infections among allograft donors
and recipients and aid healthcare personnel in
detecting, communicating, tracking and preventing
the transmission of infections.
A Transplantation Transmission Sentinel Network
(TTSN) data base prototype was created by UNOS
over a three-year cooperative agreement (and one-
year extension) with CDC. A pilot study was carried
out after development of a prototype, which led to a
number of conclusions. Unfortunately, no additional
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tion. TTSN was an important step forward in
determining the needs for a national system integrat-
ing organ and tissue safety. Lessons learned included
the need to create a partnership with two separate
industry groups, the solid organ transplant commu-
nity and tissue banking and user community. Build-
ing an adverse event system without a foundation of
existing nomenclature or tracking for tissue allografts
resulted in a daunting task to organize what is
essentially a chaotic environment. The prototype
proved that a system can be built, however, only with
an impetus from legislation or regulation to track
allograft use nationally and internationally. The lack
of a uniform labeling standard in the U.S. and other
countries, as exists for blood and blood products, may
also contribute to the problems of tracking and
traceability. The key to satisfying these requirements
lies in standardization: globally unique identiﬁers for
products, standardized terminology and a means to
convey information electronically that is recognized
by computer systems throughout the world.
Importation and exportation of cells, tissues
and organs across national boundaries
In the previously reported Biomedical Tissue Ser-
vices (BTS) scandal, there were more than 800
tissues that couldn’t be traced outside the U.S. More
than 25 hospitals in the United Kingdom alone
reported receiving tissues from this case. The AATB
reports that US tissue banks export tissue to more
than 30 countries. A survey of the 5 largest US tissue
banks demonstrated that from 2 to 8% of their
distributions are international with major markets in:
Korea, Turkey, Greece, Canada, the Middle East,
Central American, South America, Australia and the
EU. In Canada, over 90% of tissue transplanted is
imported from the U.S. In the BTS recall, Health
Canada was only able to provide approximate
estimates of the number of recalled tissue products
imported into Canada and was dependent on multiple
tissue banks and tissue importers for tracing allografts
to end users and notifying patients (Health Canada
News Release 2005). The US FDA investigations in
1993 documented the legitimate importation of tissue
by some US banks from Eastern Europe (Henkel
1994). The trafﬁcking of solid organs sold from Israel
to New York (Feyerick 2009) and the alleged theft of
tissues from Ukraine (Keller and Grill 2009) are other
examples of international trade. It is also worth
noting that donated tissue may be from a non US
source, processed in the US and issued in and out of
the US, making traceability even more complex.
For cellular therapies, the Cellular Therapy Coding
and Labeling Advisory Group began its work in 2004.
Over 40% of unrelated bone marrow donations are
transplantedinacountryotherthanthe onewhere they
were donated. Unrelated cord blood donations are
increasingly being exported around the world for stem
cell replacement. This is a steady upward trend from
just 30% in 1997. Recognizing the high proportion of
grafts crossing national borders, the US FDA pub-
lished in the Code of Federal Regulations (21CFR
1271.55),rulesgoverningimports.Theseincludedthat
cellsandtissuesmusthavedistinctidentiﬁcationcodes
that relate to the donor and to all records pertaining to
the graft. Import and export regulations of cell therapy
products are based on the FDA’s risk based approach,
recognizing the need for traceability.
Corneas are also exported on a large scale. The
Eye Bank in Sri Lanka exports corneas to 65
countries and claims to have exported over 40,000
corneas since it’s founding in 1964. It is common
practice in the US to export corneas to Africa and
South America where the need is great and the supply
scarce. Over 10,000 corneas are exported from the
US each year. The total numbers of cell, tissue and
organ exports is not known since there is no central
control or agency that captures this data.
Recognition of the need for global standardization
The need for globally unique identiﬁcation
Blood Services have long recognized the need to
ensure that each unit of blood can be individually
identiﬁed in order to relate sample test results and
cross matching outcomes to the correct unit, and to
allow tracking from donor to recipient. Initially each
blood center assigned its own numbers to the units it
collected, and ensured uniqueness of identiﬁcation
within its organization and the transfusion services it
served.
With the introduction of policies in some countries
to share blood resources between blood centers in
order to more effectively satisfy supply and demand,
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be unique at a national level to prevent duplication of
numbers in hospital transfusion laboratories. Without
this capability, patient safety is at risk as exempliﬁed
by the common problem of misidentiﬁcation of
patients and wrong blood units being transfused,
sometimes resulting in death.
The experience during the Persian Gulf War in
1990 and 1991 was the primary stimulus to solve the
labeling and coding issues. Because the military
contracted with many agencies to provide blood, the
military experienced thousands of labeling mistakes
resulting in misidentiﬁcation of units (Blood Products
Advisory Committee 1997). Additionally, during the
1990s it became increasingly common to establish
centralized testing laboratories. When multiple blood
centers submitted their samples to a single laboratory
for testing, identiﬁers were often unique only within
the context of the facility in which products were
drawn. The International Society of Blood Transfu-
sion (ISBT) established a Working Party, with
international membership from multiple countries,
which created a standardized means of labeling blood
products so that identiﬁers were globally unique and
bar codes (as well as other means of electronic
information transfer) would have the same meaning
internationally. The new coding system was named
ISBT 128, the ‘128’ in ISBT 128 comes from the
barcode symbology which was selected at the time
the standard was developed—this symbology is
called Code 128, so the ISBT coding system using
Code 128 bar codes became known as ISBT 128.
This standard was formally approved in 1994.
Although the transfer of blood across national
boundaries is not a common occurrence, the situation
for cells and tissues is very different as has been
indicated above. For this reason the case for globally
unique identiﬁcation is at least as strong as that for
blood transfusion. A globally unique identiﬁcation
system is required, and this should extend across all
biologic materials—blood, cells, tissues and organs.
Previous experience gainedfrommanagingadverse
events and reactions has led to a widespread under-
standing of the need for traceability—the ability to
track from donor to recipient and vice versa in order to
ensure that all individuals associated with an event or
reaction can be identiﬁed. Full traceability goes well
beyond the single strand of information following the
path of one product from donor to recipient, and
becomes a complex web where multiple products are
produced, pooled products are prepared, donors can
make multiple donations of different biologic materi-
als and multiple agencies can be involved in the
procurement of organs and tissues. This web of
information has multiple data owners, frequently
extends across continents, and has to be retained for
long periods of time (European Tissues and Cells
Directive requires information to be stored for
30 years from the time of clinical use).
Retaining such large amounts of information for
long periods in a format that allows rapid retrieval
demands the use of computer data storage. In order to
ensure a complete and secure information trail across
the multiple computerized systems that may be
involved, a means of uniquely identifying each dona-
tion, and each product prepared from that donation, is
essential. It is clear that uniqueness of identiﬁcation at
national or regional level is not sufﬁcient when cells,
tissues and organs can and do travel worldwide.
WHO guiding principles
WHO has held 2 global consultations on human cells
and tissues for transplantation, the ﬁrst in Ottawa in
December 2004 and the second in Geneva in June
2006, both of which resulted in reports. Participants
recognized the signiﬁcant global circulation of cer-
tain human tissues and cells and the substantial role-
played by a commercial market in many of these
tissue and cell products. Transparency in these
activities is essential to ensure public support and
understanding. A key element of oversight includes
effective systems of vigilance and surveillance
worldwide, which requires, as an essential prerequi-
site, a robust system for traceability of donated
material from donor to recipient. WHO is participat-
ing in a EU funded project that is working to develop
common systems for the reporting and management
of adverse events and reactions (EUSTITE). The
WHO has clearly stated its position concerning
coding and traceability of cells, tissues and organs.
At the Second Global Consultation on Regulatory
Requirements for Human Cells and Tissues for
Transplantation in 2006, the WHO published a
statement that ‘‘As this globalization of cells and
tissue transplantation develops, the need for common
product names and deﬁnitions for unique product
identiﬁcation becomes essential’’.
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Cell Tissue and Organ Transplantation as approved
by the 124th Executive Board in resolution 124.R13
includes Guiding Principle 10 dedicated to the
necessity of detailed assessment of transplantation
procedures as well as of the outcome of transplanted
human cells, tissues and organs. In the commentary
of Guiding Principle 10 is the following sentence:
‘‘Internationally agreed means of coding to identify
tissues and cells used in transplantation are essential
for full traceability’’.
Work carried out during and after the two Global
consultations has resulted in the development of two
WHO Aide-Memoires specifying basic requirements
in this ﬁeld. The Aide-Me ´moire on ‘‘Access to Safe
and Effective Cells and Tissues for Transplantation’’
provides an overview for National Health Authori-
ties, but also for all stakeholders, of all key aspects to
be considered and requirements to be met for the
setting up and/or the oversight of human cell and
tissue transplantation services (WHO 2009).
European directive and CEN workshop
In 2004, a European Union Directive mandated a
single coding system for cells and tissues [European
Tissues and Cells DIRECTIVE 2004/23/EC (ECD)].
To this end, the European Committee for Standardi-
zation(orComite ´ Europe ´endeNormalisationorCEN)
evaluated various standardized coding systems for use
within the European Union (CEN Workshop Agree-
ment 2008). It was recognized that ‘‘…there are real
problems with meaning-shift when using common
terms between languages. For that reason many
nomenclature schemes use a very rigid set of syntac-
tical rules to ensure that the term being coded is
capableofbeinginterpretedfaithfullyinanylanguage,
whatever its real-world syntax and grammar’’. The
report promoted ISBT 128 as the preferred option but
they also proposed allowing member states to use two
other variations (one with national ID numbers but
ISBT 128 product descriptions and one without any
internationally agreed component). They determined
that one of the major beneﬁts of ISBT 128 was that it
couldbeusedforfourgroupsofbiologics:blood,cells,
tissues and organs. The CWA work analyzed existing
relevant public activities at European, national,
regional and international levels, and also considered
relevant international activities. There were 3
candidates proposed by Member State (MS) and a
panel recommended use of ISBT 128 as the basis for
the EU coding scheme. Although it was considered a
good match to requirements, it was not perfect in its
current design. Further work was identiﬁed tomeetthe
need for an additional component to be created to
support both use of ISBT 128 and those organizations
electing to retain existing coding schemes. This new
component was temporarily named in the CEN report
as the ‘‘key code’’. Because a donation event may
result intissuessent todifferent TissueEstablishments
ICCBBA offered a new component, incorporating
Country code, Responsible organization (e.g. Compe-
tent Authority) and Tissue Establishment, to be
developed with the EU to meet international require-
ments. The Key Code would not invalidate existing
ISBT 128code structuresbutaugment them.The‘‘key
code’’ could also be used with existing coding systems
to provide unique identiﬁcation and allow EU (poten-
tially global) traceability of all materials from one
donation event. Among the other CEN CWA conclu-
sions were:
1. The ability to share coded data between different
donor sectors in the future may help with risk
prevention measures and provide clearer indica-
tions of donor suitability.
2. It may also reduce duplication and ensure better
recall management.
3. It is feasible that with technological advances in
regenerative medicine that the interfaces between
blood, tissues, cells, and organs may become less
deﬁned.
The CEN solution supports the long-term migra-
tion to ISBT 128 whilst providing a short-term
solution to unique identiﬁcation through the use of
the key code.
In transposing the EC Directive into national
legislation, some countries (notably Poland and
Austria) made the use of ISBT 128 for coding and
labeling cells and tissues a legal obligation.
Mechanisms for providing globally unique
identiﬁcation
A number of mechanisms exist for providing globally
unique identiﬁers, and in general when a large
number of items have to be identiﬁed, they work on
a layered principle. An overarching international
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organization responsible for lower level assignment,
and the sub-body assigns unique identiﬁers within its
jurisdiction. Together the two parts provide a unique
identiﬁcation. An example is the telephone number-
ing system where a United Nations Agency, the
International Telecommunications Union, assigns the
‘country code’ and the actual number of each
telephone in the country is assigned by a ‘national’
body. (Although ‘country code’ is used in this
context, it is not an exact match to country identi-
ﬁcation—for example the country code ‘1’ covers
both the USA and Canada.)
A similar mechanism is used by GS1, the supply
chain standards body that maintains the GS1 standard
used by many commercial organizations for bar
coding their products. Using GS1, each type of
product from a manufacturer can be uniquely iden-
tiﬁed using a Global Trade Item Number (GTIN).
GS1 assigns one portion of the GTIN identiﬁer to
uniquely identify each manufacturer, and the manu-
facturer assigns the second portion to uniquely
identify the type of product within their organization.
In the transfusion and transplantation ﬁeld,
ICCBBA uses a similar model by assigning a facility
code to each organization that will assign ISBT 128
donation identiﬁcation numbers (e.g. blood center,
tissue establishment, competent authority) and the
relevant organization assigning a sequence number.
In all the above cases the combination of the two
elements provides a globally unique identiﬁcation for
the item or, in the case of tissues, the donation event.
The case for bar coding and electronic data
transfer
Traceability depends not only on the use of unique
identiﬁers, but also on the accurate transcription of
those identiﬁers at all parts of the traceability chain.
The risks of error during manual transcription of
information are well documented, and in the blood
transfusion ﬁeld, which has some well-developed
hemovigilance systems, cases of incorrect blood
component transfused are a major source of adverse
events, with administrative errors in identiﬁcation
forming a major cause of these. Use of electronic
information capture provides a means of improving
safety by eliminating the risk of manual transcription
error,andspeedinguptheinformationtransferprocess.
Clearly not all countries have the necessary infra-
structure to support the use of computerized systems
throughout the transplant process, however where
systems are available they should be used, and the
ability tointroduce suchsafetymeasuresshouldnotbe
impeded by the lack of bar coded information on the
tissueproductlabel.Forthisreason,anymovetowards
adopting globally unique identiﬁcation should be
compatible with a well established standard coding
system so that the progression towards automated data
capture and computerized records can be achieved.
Coding systems
What is a coding system?
A coding system is a means by which distinct items
within a system can be uniquely identiﬁed and
consistently characterized to all participants within
that system. It requires as a minimum a means to
allocate identiﬁers in a manner that avoids duplica-
tion, and a standard reference for describing items.
The degree to which unique identiﬁcation is
required depends upon a number of factors. For a
manufactured drug identiﬁcation of the manufacturer
and the unique lot number assigned by that manu-
facturer is sufﬁcient to trace back to the manufactur-
ing records for the batch. In this situation it is
common to use a single identiﬁer for all items in the
batch. For donated biologics such as blood or tissue
each donation has unique characteristics and is thus a
‘batch’ in its own right. In such cases there is a need
for unique identiﬁcation to be at the individual
donation level, and for each product prepared from
the donation to also be individually identiﬁed.
Uniqueness within a system requires that a bound-
ary be deﬁned to the system and controls need to be in
place to ensure that the item does not travel outside the
boundary. If, for example, the system is contained
within a national boundary, then uniqueness at the
national level is adequate, but as soon as an item
travels beyond the boundary, the risk of duplication
exists.Forbiologicproducts,whichincreasinglytravel
worldwide, global uniqueness is essential.
With the increasing use of computers, coding
systems are commonly associated with information
standards to allow the coding information to be
electronically transmitted between computer systems.
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electronically readable format such as a bar code. The
information standard deﬁnes the technical speciﬁca-
tion for this electronic format thus ensuring that all
computer systems can read and write the electronic
information.
It is important to recognize that a coding system
does not itself provide traceability, but provides the
information infrastructure on which effective trace-
ability can be built. Coding and traceability are not
the same but one supports the other.
Coding systems and traceability
Previous experience gained from Blood in managing
adverse events and reactions has led to a widespread
understanding of the need for traceability—the ability
to track from donor to recipient and vice versa in
order to ensure that all individuals associated with an
event or reaction can be identiﬁed.
There is frequently confusion regarding the terms
‘coding system’ and ‘traceability system’. These are
perceived to be the same, but in fact they are quite
distinct. A coding system provides the necessary
standards and control in order to ensure that each
donation,andeachproductpreparedfromthatdonation,
isuniquelyidentiﬁed,andthatacommonterminologyis
used. A traceability system maintains records on the
activitiesassociatedwithdonatedmaterialfromthetime
of procurement to the point of implantation.
Where the full lifecycle of donated material occurs
within the boundary of a single traceability system,
the identiﬁers and terminology used can be speciﬁc to
that traceability system. However, as soon as trace-
ability responsibility is distributed across several
traceability systems there is need for an underlying
coding system that provides global uniqueness of
identiﬁcation and internationally agreed terminology.
The EU Commission Directive 2006/17/EC
deﬁnes traceability as follows:
‘Traceability’ means the ability to locate and
identify the tissue/cell during any step from
procurement, through processing, testing and
storage, to distribution to the recipient or
disposal, which also implies the ability to
identify the donor and the tissue establishment
or the manufacturing facility receiving, pro-
cessing or storing the tissue/cells, and the
ability to identify the recipient(s) at the medical
facility/facilities applying the tissue/cells to the
recipient(s); traceability also covers the ability
to locate and identify all relevant data relating
to products and materials coming into contact
with those tissues/cells.
This deﬁnition focuses on the single path from
donor to recipient; however, full traceability requires
all tissue, and arguably all biologics (blood, cells,
tissues and organs) from the same donor to be traced.
Full traceability goes well beyond the single strand of
information following the path of one product from
donor to recipient, and becomes a complex web where
multiple products are produced, pooled products are
prepared, donors can make multiple donations of
different biologic materials and multiple agencies can
be involved in the procurement of tissues. Almost
inevitably this means that the traceability path will
travel through multiple traceability systems. There
maybesituationswheretraceabilityisrequiredbeyond
a single donation where a donor may donate multiple
components via multiple establishments throughout
their life e.g. Cord blood, blood, sperm, hip bone, and
on death, organs, corneas and multi-tissues. Should a
ﬁnding occur, it may be essential to track previous
donationhistorye.g.whenHCVtestingwasintroduced
and regular blood donors were identiﬁed as having
HCV, it was essential to be able to track previous
donations (blood, cells or tissue) via traceability to
follow up potentially infected recipients. This might
mean creating a unique identity for individuals.
In addition, regulatory requirements on data
retention mean that traceability records have to be
retained in an accessible manner for long periods of
time (European Directive requires information to be
stored for 30 years from the time of clinical use).
Retaining such large amounts of information for
long periods in a format that allows rapid retrieval
demands the use of computer data storage. In order to
ensure a complete and secure information trail across
the multiple computerized systems that may be
involved, a means of uniquely identifying each
donation, and each product prepared from that dona-
tion, is essential. Uniqueness at national or regional
level is not sufﬁcient when tissue can travel world-
wide. A globally unique identiﬁcation system is
required, and this should extend across all biologic
materials—blood, cells, tissues and organs.
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traceability systems, however adopting a common
coding system simpliﬁes the interfaces between
different traceability systems and reduces the risk of
breaks in the traceability chain.
Nomenclature as a ﬁrst step in harmonizing
coding
Building an internationally standardized terminology
thatcanberepresentedinanelectronicformonalabelis
a complex activity. A useful model has been described
based on a ﬁve-layer pyramid (Ashford 2006).
The base layer of the model, on which the others
layers are built, is the Terminology. Taking individual
terms and providing a clear and unambiguous deﬁni-
tion, build the terminology. The ‘granularity’ or level
of detail of this terminology is important. Too little
detail will result in clinically distinct products having
the same name, whereas too much detail will result in
an explosion of different codes for what is essentially
the same clinical product. In order to achieve the
appropriate level of detail it is necessary to bring
togetheranexpertinternationalpanel.Theproductionof
aninternationaldictionaryprovidesawayofensuringa
common understanding of the information itself.
Once deﬁnitions have been agreed, then it is
possible to start building the reference tables that
provide the key lookup for the standard. These tables
provide the mapping from the verbal description that
is understood by users of the system, to the alpha-
numeric codes used in computer systems and elec-
tronic information carriers such as bar codes.
The Reference Tables ensure consistent interpreta-
tionofthecodedinformationacrossmultipleplatforms.
Because of the rapidly changing transfusion and trans-
plantation environment these tables need to be ﬂexible
and readily updated within a strictly managed process.
The next level is described as the ‘Data Struc-
tures’. These are only really of interest to the software
developers who write or read electronic information,
but they are an essential element as they provide the
context and deﬁne the structure for each piece of
information. The data structures make it possible for
completely different and independent computer sys-
tems to communicate effectively and safely, and
prevent erroneous interpretation.
The Data Structures package information in a
manner that allows it to be transferred in many
different formats. The means by which the informa-
tion is transferred from one place to another is the
delivery mechanism.
There are a number of different delivery mecha-
nism types. The most familiar is probably the linear
barcode. This relatively simple encoding system is
highly effective, but can only hold a relatively small
amount of information. Demands for more informa-
tion, combined with limitations on space for small
containers, are driving the need for alternatives.
Two-Dimensional (2-D) or Reduced Space Sym-
bology (RSS) codes can hold more information in a
much smaller space. Radio Frequency Identiﬁcation
(RFID) Tags have the beneﬁt of not requiring ‘line of
sight’ access to read. An effective coding system is
one that can be adapted for use in all these media
without the need to make changes to the underlying
layers of the model. The ﬁnal layer of the model is
the Labeling layer. Labeling provides the means of
physically attaching the information to the product,
and for presenting the human readable interpretation
of the information.
A critical element of the labeling strategy is to
ensure consistency between information stored in
electronic format and that which is human readable on
the label. Demand printing of bar coded labels can
achieve this as both sets of information are printed at
the same time.
Management of a coding system
A coding system in a rapidly developing ﬁeld such as
transplantation must be able to adapt to the changing
information needs of the environment and thus an
appropriate management system is an essential part
of an effective coding system. The tasks of the
management organization will include:
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in order to ensure global uniqueness of identiﬁers;
2. Maintenance of an internationally agreed termi-
nology to describe tissue products;
3. Development and maintenance of the informa-
tion standard documentation;
4. Regular updating of reference tables to reﬂect the
development of new products and processes;
5. Communication with all stakeholders to keep
them informed of changes;
6. Promotion of the standard as the global solution
for transplantation.
To achieve its objectives the management organi-
zation will need to bring together experts from around
the world to build the necessary consensus on termi-
nology and will need technical committees for appro-
priate stakeholder engagement in the development of
the standard. It will need to be a robust organization
with sufﬁcient stafﬁng and resources, and will require
a mechanism to cover its costs of operation.
Currently ICCBBA is the only organization pro-
viding a truly international coding system for biolo-
gics. Looking at the running costs of this not-for-proﬁt
organization, as presented in their annual report, one
can make an estimate of the cost of providing these
management arrangements. In 2008 this organization
operated on a budget of just under $1 m US and
provided the management of the ISBT 128 Standard
for blood, cellular therapy, and a limited number of
tissues. This is a relatively low cost considering that
across all three ﬁelds of blood, cellular therapy and
tissue there are now more than 3,700 ISBT 128
licensed facilities in 66 countries and ICCBBA
estimate that more than 40 million products are
labeled to the ISBT 128 Standard each year. There
are 237 Tissue and Cell facilities in more than 30
countries currently registered with ICCBBA (IC-
CBBA 2009) and 27 of these have registered since
the start of 2009.
Progress toward international standardization
for coding: the current situation
Blood
National standards to ensure uniqueness of donation
identiﬁcation were introduced by many countries in
the 1980s and 1990s. In some cases these were
associated with the use of bar codes such as ABC
Codabar. Some of these systems have been updated
and continue in use today; however, there is wide-
spread recognition of the limitations and weaknesses
of Codabar as a bar code symbology and of the need
to move towards an international standard. The
experience in the Gulf War with units of blood
labeled with Codabar but with multiple errors,
demonstrated its limitations (see below).
European blood banks began adopting ISBT 128 in
the late 1990s and countries in Asia and the Middle
East followed. In North America, the AABB estab-
lisheditasastandardin2008.Ithasbeenimplemented
acrossCanadaandapproximately60%oftheUSblood
supply with the remainder to be implemented follow-
ing other software upgrades. In China, blood banks in
three provinces are using ISBT 128 along with the
hospitals they serve. The Japanese Red Cross uses its
own coding system for blood within Japan.
Today ICCBBA reports that ISBT 128 is used for
blood transfusion coding and labeling in more than
3,400 blood centers and transfusion laboratories in 49
countries worldwide and that more than 40 million
blood components are identiﬁed with ISBT 128 each
year. A recent survey indicates that this ﬁgure will
continuetoriseinthecomingyears(Ashfordetal.2010).
In Germany an alternative standard (Eurocode) was
developed for blood transfusion use in 1998. This
standardhasbeenimplementedinsomebloodservices
inGermanybuthasnotgainedwidespreadrecognition.
Other countries, such as Japan, have used their own
coding systems, which are efﬁcient within the country
but are not translatable across national boundaries.
Cellular Therapy
In 2005 the Boards of Directors of AABB, American
Society for Blood and Marrow Transplantation (AS-
BMT), American Society for Apheresis (ASFA),
European Group for Blood and Marrow Transplanta-
tion (EBMT), Foundation for the Accreditation of
Cellular Therapy (FACT), ICCBBA, International
Society of Blood Transfusion (ISBT), International
Society for Cellular Therapy (ISCT), ISCT Europe,
Joint Accreditation Committee of ISCT and EBMT
(JACIE), National Marrow Donor Program (NMDP)
and the World Marrow Donor Association (WMDA)
released a Consensus Statement conﬁrming their
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coding of hematopoietic progenitor cells and other
therapeutic cell products and announcing the estab-
lishment of a co-sponsored International Cellular
Therapy Coding and Labelling Advisory Group.
This group began working to expand ISBT 128 for
use in the ﬁeld of cellular therapy. While a number of
facilities had used ISBT 128 for cellular therapy
products since the late 1990s, this group greatly
expanded the terms and deﬁnitions to meet evolving
needs. Their work was published in a variety of
journals (Ashford et al. 2007).
Beginning in 2008, ISBT 128 terminology was
required by FACT, JACIE, and AABB standards for
labeling cellular therapy products. The requirement
by these organizations for full ISBT 128 labeling (bar
codes and label design) is still a few years off to
allow for enhancement of computer systems. How-
ever, some cellular therapy facilities that also handle
blood are already in the process of implementing the
full label and nearly 200 facilities in 36 countries are
registered with ICCBBA (2008).
Currently, national coordinating centers assign
donor numbers to cellular product donations. As an
example, the NMDP assigns a donor number for each
unrelated donor of bone marrow, cord blood or
peripheral blood stems cells. If the donor gives three
products over 3 days, each has the same donor
number and the date makes the identiﬁer unique for
each product. In the future, products should be
labeled with ISBT 128 donation numbers. Products
from a donor who donates on multiple days will have
a different donation identiﬁcation number on each
product. The donor number, which is assigned by
NMDP, is in the donor record, but does not appear on
the product as the unique identiﬁer. Currently, the
donor number is unique only within the country and
thus the unique identiﬁer on the product is unique
only within the country. There is a need to move to
the system of a donation identiﬁer on each product to
be unique internationally.
Tissues
Currently identiﬁcation systems for tissues range
from the use of tissue bank assigned identiﬁers,
which are only unique within the speciﬁc tissue bank
to use of ISBT 128 globally unique identiﬁers.
In the USA, a typical numbering system is based
on the year of tissue recovery followed by a sequence
number, thus the ﬁrst recovery of 2009 is identiﬁed as
09/001. Many tissue banks use this system thus there
will be tissue grafts from multiple donors carrying the
same identiﬁer. Only when the tissue bank name is
associated with this identiﬁer is national uniqueness
ensured. This duplication of identiﬁers presents major
challenges for traceability. The Center for Disease
Control is investigating the use of a national donation
event identiﬁer to overcome these difﬁculties.
In Italy, tissue donors are assigned an identiﬁer at
the national level by the Italian competent authority.
All tissue processors, procuring tissue from the donor,
use this identiﬁer. The number is unique nationally,
but does not meet an internationallyagreed format and
is thus unlikely to be compatible with traceability
systems outside Italy.
In the UK, the National Health Service—Blood
and Tissues assigns an ISBT 128 identiﬁcation
number to all tissues it procures. This number is
unique globally and is in an international standard
format, and therefore can be read and understood by
all laboratories, inventory management and traceabil-
ity systems that support ISBT 128.
Most of the hospitals in China are using coding
systems for cells, tissues and organs. These coding
systems are usually different from one hospital to
another; however, the coding for patient ID is unique
in every city originally for insurance purposes. This is
how a patient and his/her medical history can be
traced within/among one/different hospital(s). There
is little use of ISBT 128 at this stage.
Attempts at standardizing nomenclature have had
limited success throughout the world. For the most
part, individual Tissue Banks have their own labeling
and coding scheme, which is not readable by
recipient hospitals and surgery centers except through
manual entry. Exceptions do exist, for example, The
National Health Service Blood and Transplant Tissue
Services in the United Kingdom was the ﬁrst to
recognize the importance of international standardi-
zation of coding for tissues. They worked with
ICCBBA to develop appropriate terminology and to
adapt the ISBT 128 Standard to the needs of tissue
banking. They fully implemented ISBT 128 for tissue
in 2003 (Fehily et al. 2004). Since then, facilities in
other countries, including Poland, Finland and Den-
mark have implemented the standard. Austria has a
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have not yet done so.
ICCBBA has set up a European Tissue Technical
Advisory Group (ETTAG) and is in the process of
establishing an international advisory group for eye
banking. The ETTAG will focus on the speciﬁc
challenges facing European countries implementing
ISBT 128 and will work with the EC to develop the
key code identiﬁed in the CEN report. In the US,
ICCBBA has been working with the North American
Tissue Technical Advisory Group (NATTAG) of the
AATB to establish common terminology for tissue
products, the ﬁrst step in the standardization process.
When this expert panel reaches consensus, their
document will be circulated for comment among
AATB members. Comments will be taken into
consideration and ﬁnal draft shared for international
comment. When international consensus for termi-
nology attained, terminology will be added to ISBT
128 Standard Terminology for Blood, Cellular Ther-
apy and Tissue Product Descriptions.
Additionally, ICCBBA has developed a proposal
for a two-phase implementation of ISBT 128 that may
be a model for implementation in countries that are
unable to move directly to full ISBT 128 labeling. The
proposal uses a small ISBT 128 label (approx
35 mm 9 35 mm) and, as a ﬁrst phase, would carry
a bar coded and eye readable ISBT 128 identiﬁcation
number with a generic product code indicating the
product to be human tissue but without further
deﬁnition. The ISBT 128 number could be in addition
to any local numbering for an interim period allowing
time for local systems to be updated to use the new
number format.
Once terminology has been agreed, the second
phase incorporates the product code onto the label
with minimal design change. The proposal also
introduces the possibility of using 2-dimensional
(Datamatrix) codes as a means of encoding more
information in the space available.
Organs
As with tissue, in some countries, organ donors are
assigned an identiﬁer at the national level by the
competent authority such as in Italy, or a government
designated authority, such as the United Network for
Organ Sharing (UNOS) in the U.S. This identiﬁer is
used by the organ recovery agency and is assigned to
all organs recovered from a particular donor. The
number is unique nationally, but does not meet an
internationally agreed format and is thus unlikely to
be compatible with traceability systems outside of the
country of origin or countries that participate in the
assigned system, such as Eurotransplant. This number
is also not universally shared with the tissue recovery
agencies that recover tissue from the same donor.
Thus, the linkage is broken and communication is
difﬁcult. If an adverse event is recognized by one
program, usually in the organ transplant recipient,
mechanisms are lacking to convey this information to
the multiple agencies involved outside of the organ
transplant community. This was a serious gap recog-
nized by the CDC in designing the TTSN.
One example of such a coding system that is
currently being used for solid organ donors is the
alphanumeric scheme used in the United States since
the inception of the Organ Procurement and Trans-
plantation Network (OPTN) in 1987. UNOS main-
tains a computer system (UNet
SM) where all
information about organ donors, candidates and
actual organ recipients are stored. When an Organ
Procurement Organization (OPO) has a potential
deceased organ donor, they access the UNet
SM
system and generate a unique six-character alphanu-
meric Donor ID. The OPO uses UNet
SM to make
electronic offers to the transplant programs of the
candidates on the list. When an organ is transplanted,
the transplant program uses UNet
SM to enter infor-
mation on the recipient and the donor and the UNOS
Donor ID links the two within the computer system.
When a disease transmission is reported to the
OPTN Patient Safety System, UNOS staff can easily
access the information about all other recipients of
organs from the donor and contact the transplant
programs that performed the transplant. The OPO is
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recovered and/or processed the tissue recovered from
the donor. Note that UNet
SM is not used to generate a
UNOS Donor ID in the case of a tissue-only donor.
There is currently no single coding system in the
United States that is used for all organ and tissue
donors.
Software and instruments
To maximize the safety and efﬁciency beneﬁts of
electronic data capture it is important to ensure that
instruments and software used throughout the path-
way from donor to recipient are able to read and
correctly interpret the information provided in elec-
tronically readable format. The cost of modiﬁcation
of software and instruments to accommodate locally
designed systems is high. Manufacturers will only
include support for a coding system as a standard
feature of their product if the market is sufﬁciently
large. This presents a major obstacle for any new
coding system—as illustrated by the case of ISBT
128 where it took almost ten years from the
development of the standard until a signiﬁcant
number of manufacturers would support it as a
standard feature. Today, ﬁfteen years after ISBT 128
was developed, almost 100 vendors of software,
instruments, and containers and labels are licensed
with ICCBBA and support the ISBT 128 Standard.
Many of these suppliers provide products that are
used across all sectors (e.g. blood grouping machines,
infectious disease screening systems). Several of the
major software systems providers in the blood
transfusion ﬁeld that support ISBT 128 are now
marketing systems to support cellular therapy and
tissues.
Coding systems for cells, tissues and organs:
lessons learned and a path forward
Lessons learned and the value of a coding system
common to substances of human origin
A number of lessons from the past decade can be
applied to issues of traceability and coding. The
safety and traceability beneﬁts of uniform identiﬁca-
tion combined with electronically readable informa-
tion were recognized in the blood transfusion ﬁeld as
far back as 1976 when a system using Codabar bar
codes was introduced in 16 blood centers and
transfusion services in the US as part of a test
program coordinated by the American Blood Com-
mission. Following the success of this program the
ABC-Codabar standard was widely adopted in the US
and in several other countries (Brodheim et al. 1980;
Thatcher 1981). Whilst highly successful for many
years, this standard was designed for use in a ‘local’
context at a time when there was little movement of
blood or samples outside the local blood center
region, transfusion records were stored for periods of
only a few years, and only a small range of blood
components was prepared.
With the rapid growth in component therapy,
combined with the move to larger and more central-
ized blood centers and testing facilities, the ABC-
Codabar standard was unable to cope with the more
complex demands. Donation identiﬁcation ‘unique-
ness’ was constrained to the local provider (i.e. two
different blood center providers could use the same
‘unique’ identiﬁer). Locally introduced ‘ﬁxes’ to
accommodate new codes into the old structure
undermined the original elements of commonality
in the standard. As previously noted, the Gulf War
emphasized the weakness of this system and stimu-
lated the development of a new, internationally
recognized machine-readable system.
There continues to be resistance to changing to an
international standard due to a variety of reasons.
There are inherent costs related to changing coding
and labeling including software and hardware invest-
ments along with the inherent resistance to any
change per se. This applies to both suppliers and
customers who have to coordinate their systems to be
compatible. There is also a small fee to register the
individual institution in order to identify the sources
of materials. Nevertheless, cost savings are also
achieved over the long term, including personnel
costs realized by adopting a standardized coding
system. As an example, Diana Teo (Director of
Singapore Blood Services) in the ICCBBA annual
report is quoted: ‘‘ISBT 128 has provided us with an
organized and consistent system of labeling for our
blood and blood components. This has enabled better
monitoring and more efﬁcient management of our
blood inventory. The unique format of the donation
identiﬁcation and product code has also contributed
towards blood safety. Ultimately, the change to
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Singapore.’’
There has also been resistance to the adoption of a
‘blood’ standard for tissue products, however the
ISBT 128 system has already been demonstrated to
meet the needs of tissue banking, and ICCBBA have
gone to considerable lengths to engage with the tissue
and cell communities by appointing experts from
these ﬁelds to their Board of Directors and establish-
ing technical advisory groups in these ﬁelds. The
beneﬁts of a single coding system for products of
human origin, both in terms of simpliﬁed handling
within the hospitals, and improved biovigilance, are
clear.
Currently, tissue that is received into a hospital
inventory can come from as many as 40 different
suppliers, each with a different labeling system and
most of which are not machine-readable. This adds
signiﬁcant burden to the management of inventory
requiring signiﬁcant labor investment to log in each
tissue both as received and when distributed within
the hospital environment. This obviously increases
risks to patient safety as it creates opportunities for
error and increases the difﬁculty of traceability as
well as the costs associated with these.
Recommendations for a path forward
There is currently a wide diversity in the identiﬁca-
tion and coding of tissue and cell products. Identi-
ﬁcation numbers are very often only unique to the
cell processing laboratory or tissue bank of issue and
are not always provided in an electronically readable
format. Product terminology is generally not stan-
dardized even at the national level. Label design and
content is varied although regulatory requirements
ensure essential information is present. However,
there is a slow but steady trend towards the imple-
mentation of ISBT 128. Two hundred and thirty-
seven Tissue and Cell facilities in more than 30
countries are currently registered with ICCBBA to
use ISBT 128, and 27 of these have registered since
the start of 2009. Across all three ﬁelds of blood,
cellular therapy and tissue there are now more than
3,700 ISBT 128 licensed facilities in 66 countries.
The international consensus on cellular therapy
coding and labeling has set a clear direction for the
global adoption of ISBT 128 for CT products. Interest
in the tissue banking sector continues to grow,
particularly with the recognition of the essential need
for globally unique identiﬁcation of tissues, however
the lack of clarity over the European Commission’s
position on coding is hampering adoption in some
European countries.
Effective traceability and biovigilance in the
global context depends upon the use of globally
unique identiﬁcation for all donated biologic prod-
ucts. Where technological development permits, such
identiﬁcation should be provided in a standard
electronically readable format to eliminate the risk
of manual transcription errors. The ISBT 128 system
has already been adopted in many countries, is well
established, and is reliable.
In most cases mapping from existing local or
national numbering systems to an ISBT 128 number
should be relatively simple. The ISBT 128 Facility
Identiﬁer can be assigned at the level of individual
tissue banks or organ procurement organizations, or
at the level of a national coordination body. The
remainder of the identiﬁer is made up of a two-digit
year code, and a six-digit sequence number. As an
example, a tissue bank in the USA may currently
identify tissue donations using a year code (09) and
sequence number in the year (001), giving the ﬁrst
donor of 2009 the number 09/001. If this tissue bank
were assigned the ISBT 128 facility code of W9999,
then the number would map into an ISBT 128
number as W9999 09 000001, where W9999 is the
facility code, 09 is the year and 000001 the sequence
number for the year.
Recognizing that existing systems will need to be
modiﬁed to change from current numbers to globally
unique identiﬁers a two phase proposal from IC-
CBBA could be considered as an interim step.
Previously concerns have been expressed about the
status of ICCBBA, in particular whether the organi-
zation is a commercial entity, and whether it is ‘US-
centric’. In response to such queries, ICCBBA has
conﬁrmed that they are a tax-exempt not-for-proﬁt
organization under Section 501 (c) (3) of the Inland
Revenue Code which requires that the organization
must not be organized or operated for the beneﬁt of
private interests, and no part of their organization’s
net earnings may inure to the beneﬁt of any private
shareholder or individual (IRS.gov 2010). In addition,
an international volunteer Board of Directors governs
ICCBBA with current members from Canada,
China, Denmark, Egypt, Italy, the Netherlands, and
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UK. Other resistance/perception issues include:
ICCBBA is not under the auspices of government
and there is perceived risk of the system collapsing if
ICCBBA fails without funding guarantees.
There are issues around who ultimately owns and
controls the standard and has ultimate power over it.
Another issue is the fact that the tissue banking ﬁeld
is competitive (and in some cases commercial) with
slight variations in products using patented technol-
ogies creating unique marketable ‘edges’ which
conﬂicts with the principle of commonality and
product equivalence. Finally the labeling system
‘looking the same’ is against the principle of product
branding, and highly processed grafts having unique
trade names rather than product descriptions further
exacerbates the issue.
Nevertheless, International standardization of ter-
minology helps to reduce the risk of misunderstand-
ing when product is shipped internationally and
would greatly assist in the analysis of adverse events
and reactions. To date the most comprehensive
international terminology for biologic product
descriptions is held by ICCBBA for use in the ISBT
128 Standard. However, there are some areas, most
notably in reproductive tissues, eyes and organs,
where the terminology has yet to be fully deﬁned. In
addition, efforts are needed to create communication
pathways between the different transplant communi-
ties where a donor is shared, such as with organs,
tissues and cornea programs. The identiﬁcation of an
adverse event, that may impact other recipients of
biological components from the same donor, must be
communicated to all stakeholders to improve patient
safety and outcomes.
It is recommended that:
• Efforts be made to encourage the introduction of a
standardized international coding system for
donation identiﬁcation numbers, such as ISBT
128, for all donated human biologic products.
• Focus on global traceability for all donated
human biologic products.
• Encourage communication between international
stakeholders to develop consensus on common
grounds.
• Promote suitable international forums to be
established to expand the international terminol-
ogy for donated human biologic materials.
• Any move towards adopting globally unique
identiﬁcation should be compatible with a well
established standard coding system so that the
progression towards automated data capture and
computerized records can be achieved.
References
Ahn J, Cohen SM (2008) Transmission of human immunode-
ﬁciency virus and hepatitis C virus through liver trans-
plantation. Liver Transplant 14(11):1603–1608
Albee FH (1912) Discussion of Carrell A: the preservation
of tissues and its application in surgery. JAMA 59:527–
528
Ashford P (2006) ISBT 128—improving security by interna-
tional standardization. ISBT Sci Ser (1):242-245
Ashford P, Distler P, Gee A, Lakester A et al (2007) Termi-
nology and labeling of cellular products: 1 Standards.
Bone Marrow Transpl 40:1075–1083
Ashford P, Fearon M, Bedford R (2010) Report on the joint
IBEPAG/ICCBBA survey on import/export and blood
component labeling. Vox Sang 98:85–86
Billingham RE, Medawar PB (1951) The technique of free skin
grafting in mammals. J Exp Biol 28(3):385–402
Blood Products Advisory Committee (1997) Center for Biol-
ogics and Evaluation. In: Proceedings of BPAC meeting,
June 20, 1997 http://www.fda.gov/ohrms/dockets/ac/97/
transcpt/3304t2.rtf. Accessed 11 Dec 2009
Brodheim E, Ying W, Hirsh RL (1980) An evaluation of the
Codabar symbol in blood banking automation. Vox Sang
40(3):175–180
Bush LF, Garber CL (1948) The bone bank. JAMA 137:
588–594
Carel A (1912) The preservation of tissues and its application
in surgery. JAMA 59:523–527
CEN Workshop Agreement, CWA (2008) 15849. CEN
Workshop Agreement on ‘Coding of Information and
Traceability of Human Tissues and Cells’ CWA_Coding-
for-T-and-C_v2000_20080522.doc. ftp://cenftp1.cenorm.
be/PUBLIC/CWAs/e-Europe/Tissues_cells/CWA15849-
2008-publishedtext.pdf. Accessed 6 Nov 2009
Chaney A (2006) ‘‘Body Brokers’’, Random House
CIBMTR Progress Report (2008) January–December
DeBoer HH (1986) The history of bone grafts. Clin Ortho Relat
Res 226:292–298
Eastlund T, Strong DM (2004) Infectious disease transmission
through tissue transplantation. In: Phillips GO (ed)
Advances in tissue banking, vol 7. World Scientiﬁc Pub-
lishing Company, Singapore, pp 51–131
Eisenbrey AB, Eastlund T (eds) (2008) Hospital tissue man-
agement: a practitioner’s handbook. AABB Press
Federal Register (2005) 70(106):32620–32624
Fehily D, Ashford P, Poniatowski S (2004) Traceability of
human tissues for transplantation—the development and
implementation of a coding system using ISBT 128.
Organs Tissues 2:83–88
322 Cell Tissue Bank (2010) 11:305–323
123Feyerick D (2009) Mayors, rabbis arrested in corruption probe.
CNN.com/crime. http://edition.cnn.com/2009/CRIME/07/
23/new.jersey.arrests/index.html. Accessed 4 Sept 2009
Fishman JA (2007) Infection in solid organ transplant recipi-
ents. N Eng J Med 357:2601–2614
Fishman JA, Strong DM, Kuehnert MJ (2009) Organ and tissue
safety workshop 2007: advances and challenges. Cell
Tissue Bank 10:271–280
Gandhi MJ, Strong DM (2007) Donor derived malignancy: a
review. Cell Tissue Bank 8(4):267–286
IRS.gov (2010) http://www.irs.gov/charities/charitable/article/
0,,id=123297,00.html. Accessed 2 Feb 2010
Guild WR, Harrison JH, Merrill JP, Murray J (1955–1956)
Successful homotransplantations of the kidney in identical
twins. Trans Am Clin Climatol Assoc 67:167–173
Health Canada News Release (2005) 2005-115 Tissue Recall in
the United States, October 2005
Henkel J (1994) FDA consumer magazine, vol 28, September
1994
Herman AR (2002) The history of skin grafts. J Drugs
Dermatol 1(3):298–301
ICCBBA (2008) ISBT 128 cellular therapy coding and labeling
advisory group 2008—a year end review, Annual Report,
2008
ICCBBA (2009) http://iccbba.org/info_abouticcbba.html.
Accessed Dec 2009
Internal Revenue Service (2010) http://www.irs.gov/charities/
charitable/article/0,,id=96099,00.html. Accessed 2 Feb
2010
Ison MG, Hager J, Blumberg E et al (2009) Donor-derived
disease transmission events in the United States: data
reviewed by the OPTN/UNOS disease transmission
advisory committee. Am J Transpl 9(8):1929–1935
Keller M, Grill M (2009) Inside a Creepy Global Body Parts
Business. http://www.spiegel.de/international/europe/0,1518,
645375,00.html. Accessed 4 Sept 2009
Moffat SC, Cartwright VA, Stumpf PH (2005) Centennial
review of corneal transplantation. Clin Exp Ophthalmol
33(6):642–647
Mroz TE, Joyce MJ, Steinmetz MP, Lieberman IH, Wang JC
(2008) Perspectives in modern orthopaedics. Musculo-
skeletal Allograft Risks and Recalls in the United States.
J Am Acad Orthop Surg 3(10):559–565
Phillips G, Strong DM (1997) The contribution of the inter-
national atomic energy agency to tissue banking. Cell
Tissue Rep 4(1):5–9
Strong DM (2000) The U.S. Navy Tissue Bank: 50 years on
the cutting edge. Cell Tissue Bank 1:9–16
Thatcher R (1981) Recommendations of the task force on
codes and machine-readable symbols. Vox Sang 40(3):
144–155
Thomas ED, Lochte HL, Lu WC et al (1957) Intravenous
infusion of bone marrow in patients receiving radiation
and chemotherapy. N Engl J Med 157:491–496
Trotter JF (2008) Infectious disease risk factors of corneal graft
donors. Arch Ophthalmol 126(2):235–239
Tugwell BD, Patel PR, Williams IT et al (2005) Transmission
of hepatitis C virus to several organ and tissue recipients
from an antibody-negative donor. Ann Intern Med
143:648–654
Warren J (2006) BTS stolen body parts scandal generating
gruesome headlines, fears of infection; NY grand jury
meeting. Transplant News, 16(1(Jan 13))
WHO (2005) Guidance on adverse event reporting and learn-
ing systems. http://www.who.int/patientsafety/events/05/
Reporting_Guidelines.pdf
WHO (2006) Human organ and tissue transplantation. Trans-
plantation 79:635
WHO (2009) Aide-Me ´moire on Access to Safe and Effective
Cells and Tissues for Transplantation. http://www.who.
int/transplantation/cell_tissue/en/. Accessed Nov 2009
Wilson PO (1947) Experience with a bone bank. Ann Surg
126:932–946
Cell Tissue Bank (2010) 11:305–323 323
123